Co-diagnostics, INC Form 4 insider transactions

Dwight H. Egan, CEO of Co-Diagnostics, Inc., reported transactions involving restricted stock units and common stock.

Co-Diagnostics CFO Brian Lee Brown reports transactions involving restricted stock units and common stock, including a sale to cover tax withholding obligations.

Richard David Abbott, President of Co-Diagnostics, Inc., reported transactions involving restricted stock units and common stock, including a sale to cover tax withholding obligations.

Edward L. Murphy, a Director at Co-Diagnostics, Inc., reported transactions involving restricted stock units and common stock.

Richard S. Serbin, a Director at Co-Diagnostics, Inc., reported a transaction involving the acquisition of 1,695 shares of common stock on May 23, 2026.

Eugene Durenard, a Director at Co-Diagnostics, Inc., reported transactions involving restricted stock units and common stock.

Director James B. Nelson acquired 1,695 shares of Co-Diagnostics, Inc. common stock on May 23, 2026, as part of a restricted stock unit award.

Co-Diagnostics Director Edward L. Murphy increased his beneficial ownership of common stock through the vesting of previously awarded restricted stock units.

Co-Diagnostics, Inc. Chief Financial Officer Brian Lee Brown reported the vesting of restricted stock units and a subsequent mandatory sale of shares to cover tax obligations.

Co-Diagnostics President Richard David Abbott reported the vesting of 56,667 restricted stock units and the sale of 17,200 shares to cover tax obligations.

Co-Diagnostics CEO Dwight H. Egan reported the vesting of restricted stock units and a mandatory 'sell to cover' transaction for tax obligations.

Co-Diagnostics Director Richard S. Serbin reported the acquisition of 57,499 shares of common stock through the vesting of restricted stock units.

Co-Diagnostics, Inc. Director Eugene Durenard reported the acquisition of 57,499 shares of common stock through the vesting of restricted stock units.

Co-Diagnostics Director James B. Nelson acquired 57,499 shares of common stock and restricted stock units through vesting events.

Co-Diagnostics, Inc. President Richard David Abbott was granted 220,000 Restricted Stock Units (RSUs) under the company's long-term incentive plan.

Co-Diagnostics, Inc.'s Chief Financial Officer, Brian Lee Brown, was granted 225,000 Restricted Stock Units under the company's long-term incentive plan.

Co-Diagnostics, Inc. CEO Dwight H. Egan was granted 275,000 Restricted Stock Units, aligning executive compensation with long-term shareholder value.

Co-Diagnostics, Inc. director Eugene Durenard was granted 125,000 restricted stock units under the company's 2015 Long Term Incentive Plan.

Co-Diagnostics, Inc. Director James B. Nelson was granted 125,000 Restricted Stock Units under the company's 2015 Long Term Incentive Plan.

Co-Diagnostics, Inc. Director Richard S. Serbin was granted 125,000 Restricted Stock Units, vesting in six installments starting November 2025.

Co-Diagnostics, Inc. Director Ted Murphy was granted 125,000 restricted stock units, aligning his interests with shareholders.

Co-Diagnostics, Inc. CEO Dwight H. Egan reported the acquisition of 163,334 shares of common stock through restricted stock unit vesting and the subsequent sale of 51,697 shares to cover tax obligations.

Co-Diagnostics, Inc.'s Chief Financial Officer, Brian Lee Brown, reported the vesting of 134,166 restricted stock units and the subsequent sale of 48,161 shares to cover tax obligations.

Co-Diagnostics, Inc. President, Richard David Abbott, reported the vesting of restricted stock units and a subsequent mandated sale of shares to cover tax obligations.

Co-Diagnostics, Inc. Director Richard S. Serbin reported the acquisition of 48,334 shares of common stock on May 23, 2025, resulting from the vesting of previously awarded Restricted Stock Units (RSUs), increasing his direct beneficial ownership to 214,167 shares.

Co-Diagnostics, Inc. Director Ted Murphy reported the acquisition of 48,334 shares of common stock on May 23, 2025, resulting from the vesting of restricted stock units.

Co-Diagnostics, Inc. Director Eugene Durenard acquired 48,334 shares of common stock through the scheduled vesting of restricted stock units, increasing his direct beneficial ownership to 211,667 shares.

Co-Diagnostics, Inc. Director James B. Nelson reported the acquisition of 48,334 shares of common stock through the vesting of restricted stock units on May 23, 2025, increasing his direct beneficial ownership.

Co-Diagnostics CFO Brian Brown acquired shares through vesting of restricted stock units and sold shares to cover tax obligations on November 23, 2024.

Co-Diagnostics President Richard Abbott acquired 20,000 shares of common stock through the vesting of restricted stock units and sold 6,085 shares to cover tax obligations.